Skip to main content
      RT @DrCassySims: Are my patients represented in PsA trials? @RheumNow #ACR22

      Abstract #0090; Ignite Talk
      ☝️Of 25 R

      Catherine Sims, MD DrCassySims

      3 years 10 months ago
      Are my patients represented in PsA trials? @RheumNow #ACR22 Abstract #0090; Ignite Talk ☝️Of 25 RCT from 2002-2022, only 13 included patients of non-White race ☝️Hispanic/Latinx ethnicity was reported in 0 studies ☝️Black individuals represented < 1% patients included
      RT @DrCassySims: Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now

      Catherine Sims, MD DrCassySims

      3 years 10 months ago
      Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22
      RT @Yuz6Yusof: #ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID a

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
      RT @synovialjoints: Key points in managing MDA5+ DM

      1. Monitor lungs - HRCT/PFTs
      2. Test muscle endurance (ref: IMACS

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Key points in managing MDA5+ DM 1. Monitor lungs - HRCT/PFTs 2. Test muscle endurance (ref: IMACS site) not just strength 3. Close observation 4. MTX/MMF initial treatments 5. Repeat muscle biopsy if diagnosis unclear Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2
      RT @synovialjoints: Key points in managing MDA5+ DM

      1. Consider Tofacitinib 5-10mg bd
      2. Low to mid dose Prednisolone 2

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Key points in managing MDA5+ DM 1. Consider Tofacitinib 5-10mg bd 2. Low to mid dose Prednisolone 20-30mg tapering 3. Other Rx: Tacrolimus, IVIG 4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw
      RT @synovialjoints: Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA. Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU
      RT @synovialjoints: Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0
      RT @synovialjoints: “The Stone Age did not end because of a shortage of stones. We need new solutions to our problemsâ

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      “The Stone Age did not end because of a shortage of stones. We need new solutions to our problems” Abraham Verghese. Amazing insight into our challenges in clinic today at the #ACR22 opening session @RheumNow
      RT @drdavidliew: GCA Fast Track clinics are nice - but usually need specialized ultrasound.
      What if you don't have it? (

      David Liew drdavidliew

      3 years 10 months ago
      GCA Fast Track clinics are nice - but usually need specialized ultrasound. What if you don't have it? (also, COVID?) @PennRheum implemented *without* ultrasound Excellent outcomes The early referral triage makes all the difference. Knowledge is power ABST0463 #ACR22 @RheumNow https://t.co/rjkVERW559
      RT @drdavidliew: More details at https://t.co/4U8v7oeUYW

      Enormously powerful in these times of rheumatology workforce s

      David Liew drdavidliew

      3 years 10 months ago
      More details at https://t.co/4U8v7oeUYW Enormously powerful in these times of rheumatology workforce shortage. I would love to see this in Australia and elsewhere - so much to learn. Congratulations to all involved, and thanks @ACRheum and @UCSF for supporting #ACR22
      RT @DrTrishHarkins: Just published! QR code attached! #ACR22 @RheumNow https://t.co/lMD0mFoT4M

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      Just published! QR code attached! #ACR22 @RheumNow https://t.co/lMD0mFoT4M
      RT @DrTrishHarkins: “Rheumatic diseases - diseases of accelerated aging”

      With age:
      ⚖️ fat ⬆️
      💪🏻 mus

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      “Rheumatic diseases - diseases of accelerated aging” With age: ⚖️ fat ⬆️ 💪🏻 muscle ⬇️ 👉 results in ⬇️fn ⬇️gait speed ⬇️grip 🌟what can we do? ⚡️start with basic diet and exercise advice ✅caloric restriction (⬇️350cal/day) ✅ resistance training #GeriRheum #ACR22 https://t.co/6KRrwCWBEZ
      RT @RichardPAConway: Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU &lt;6mg/dl. Inf

      Richard Conway RichardPAConway

      3 years 10 months ago
      Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G
      RT @RichardPAConway: England et al. Influence of FVC on choice of b/tsDMARD in RA-ILD. FVC predicts hospitalisation and

      Richard Conway RichardPAConway

      3 years 10 months ago
      England et al. Influence of FVC on choice of b/tsDMARD in RA-ILD. FVC predicts hospitalisation and mortality. However, it did not appear to influence choice of b/tsDMARD. Overall 67% of RA-ILD patients initiated TNFi, weird! @rheumnow #ACR22 Abstr#245 https://t.co/swuNHv96WD https://t.co/vy5FUPnNjo
      RT @uptoTate: Interesting observation: Late-onset PsA assoc'd w/ male sex, greater structural damage, higher frequency o

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Interesting observation: Late-onset PsA assoc'd w/ male sex, greater structural damage, higher frequency of arthritis, and greater loss of functionality (BASFI). Interestingly, shorter time of symptom duration to dx. Abs 0377 #ACR22 @RheumNow https://t.co/m15c37FltD https://t.co/3LRy4Ltde6
      ×